Rep. Tim Moore Buys Genprex (NASDAQ:GNPX) Stock

Representative Tim Moore (R-North Carolina) recently bought shares of Genprex (NASDAQ:GNPX). In a filing disclosed on January 07th, the Representative disclosed that they had bought between $1,001 and $15,000 in Genprex stock on December 18th.

Representative Tim Moore also recently made the following trade(s):

• Purchased $15,001 – $50,000 in shares of Cracker Barrel Old Country Store (NASDAQ:CBRL) on 12/31/2025.
• Purchased $15,001 – $50,000 in shares of Harley-Davidson (NYSE:HOG) on 12/18/2025.
• Purchased $15,001 – $50,000 in shares of Cracker Barrel Old Country Store (NASDAQ:CBRL) on 12/16/2025.
• Purchased $15,001 – $50,000 in shares of Verizon Communications (NYSE:VZ) on 12/10/2025.
• Sold $50,001 – $100,000 in shares of Cracker Barrel Old Country Store (NASDAQ:CBRL) on 12/10/2025.
• Purchased $50,001 – $100,000 in shares of Cracker Barrel Old Country Store (NASDAQ:CBRL) on 12/9/2025.
• Purchased $15,001 – $50,000 in shares of Harley-Davidson (NYSE:HOG) on 12/9/2025.
• Sold $100,001 – $250,000 in shares of Hyster-Yale (NYSE:HY) on 12/3/2025.
• Sold $15,001 – $50,000 in shares of Cracker Barrel Old Country Store (NASDAQ:CBRL) on 11/28/2025.
• Sold $15,001 – $50,000 in shares of Harley-Davidson (NYSE:HOG) on 11/28/2025.

Genprex Trading Up 10.0%

NASDAQ:GNPX opened at $2.20 on Friday. The stock has a 50-day moving average price of $2.97 and a 200 day moving average price of $8.60. The stock has a market capitalization of $6.86 million, a P/E ratio of -0.08 and a beta of -0.81. Genprex has a 12-month low of $1.71 and a 12-month high of $55.00.

Genprex (NASDAQ:GNPX) last posted its quarterly earnings results on Friday, November 14th. The company reported ($5.00) earnings per share for the quarter, topping the consensus estimate of ($12.50) by $7.50. On average, research analysts predict that Genprex will post -5.7 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on GNPX shares. Weiss Ratings restated a “sell (e+)” rating on shares of Genprex in a research report on Wednesday, October 8th. Wall Street Zen upgraded Genprex to a “sell” rating in a research report on Saturday, October 18th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has a consensus rating of “Sell”.

Hedge Funds Weigh In On Genprex

An institutional investor recently raised its position in Genprex stock. Susquehanna International Group LLP lifted its holdings in Genprex (NASDAQ:GNPX) by 11.7% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 340,056 shares of the company’s stock after buying an additional 35,661 shares during the period. Susquehanna International Group LLP owned about 27.20% of Genprex worth $58,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 14.05% of the company’s stock.

About Representative Moore

Timothy K. Moore (Republican Party) is a member of the U.S. House, representing North Carolina’s 14th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Moore (Republican Party) ran for election to the U.S. House to represent North Carolina’s 14th Congressional District. He won in the general election on November 5, 2024.

Moore served as speaker of the House from 2015 to 2025.

Timothy Moore earned his B.A. from the University of North Carolina-Chapel Hill in 1992 and his J.D. from the Oklahoma City University School of Law in 1995. His professional experience includes working as an attorney.

Genprex Company Profile

Genprex, Inc is a clinical-stage gene therapy company focused on developing novel, first-in-class treatments for cancer and diabetes. Its proprietary technology employs targeted nanoparticle delivery of therapeutic genes designed to address the underlying genetic drivers of disease. Genprex’s lead oncology candidate, Oncoprex immunogene therapy, is being evaluated for patients with non-small cell lung cancer, with the goal of restoring tumor suppressor function and enhancing response to existing targeted therapies in clinical trials across the United States.

In addition to its oncology pipeline, Genprex is advancing GPTX-203, a gene therapy candidate aimed at improving pancreatic beta-cell function in patients with type 1 diabetes.